Gossamer Bio (GOSS) reported third-quarter 2026 revenue of $38.4 million and a net loss of $48.1 million, or $7.36 per share. The company submitted a New Drug Application to the U.S. Food and Drug Administration in September for seralutinib in pulmonary arterial hypertension.
Cash, cash equivalents and marketable securities totaled $51.2 million as of September 30, 2026. Gossamer also completed a 1-for-80 reverse stock split during September.
- Third-quarter revenue from contracts with collaborators was $38.4 million, compared with $13.3 million a year earlier.
- R&D expense was $18.8 million, down from $45.5 million in the prior-year quarter.
- G&A expense was $9.6 million, compared with $9.4 million a year earlier.
- A structured private placement delivered approximately $25 million in initial gross proceeds and provides for up to approximately $125 million upon FDA acceptance of the NDA, subject to conditions.
- Seralutinib has not been approved by any regulatory authority.
$GOSS Hedge Fund Activity
We have seen 61 institutional investors add shares of $GOSS stock to their portfolio, and 115 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- D. E. SHAW & CO., INC. added 40,760,576 shares (+20512.7%) to their portfolio in Q2 2026, for an estimated $6,709,190
- DEEPCURRENTS INVESTMENT GROUP LLC added 37,665,073 shares (+inf%) to their portfolio in Q2 2026, for an estimated $6,199,671
- 683 CAPITAL MANAGEMENT, LLC added 34,198,868 shares (+684.0%) to their portfolio in Q2 2026, for an estimated $5,629,133
- WORTH VENTURE PARTNERS, LLC added 25,017,881 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,117,943
- GSA CAPITAL PARTNERS LLP added 14,935,087 shares (+28798.9%) to their portfolio in Q2 2026, for an estimated $2,458,315
- RENAISSANCE TECHNOLOGIES LLC added 10,412,028 shares (+854.9%) to their portfolio in Q2 2026, for an estimated $1,713,819
- BLACKROCK, INC. removed 9,156,752 shares (-54.4%) from their portfolio in Q2 2026, for an estimated $1,507,201
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
